[Federal Register Volume 88, Number 45 (Wednesday, March 8, 2023)]
[Notices]
[Pages 14372-14373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04697]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)--RFA-PS23-001, Increasing PrEP Use Among 
Disproportionately Affected Populations in the United States and RFA-
PS23-003, Exploring Preferences for Long-Acting Antiretroviral 
Therapies (LA-ART) in a Community-Based Sample of Priority Populations 
Living With HIV Who Are Disproportionately Affected; Amended Notice of 
Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP)--RFA-PS23-001, Increasing PrEP Use Among Disproportionately 
Affected Populations in the United States and RFA-PS23-003, Exploring 
Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a 
Community-Based Sample of Priority Populations Living with HIV Who are 
Disproportionately Affected, May 11-12, 2023, 10 a.m.-5 p.m., EDT, 
Teleconference, Centers for Disease Control and Prevention, Room 1077, 
8 Corporate Blvd., Atlanta, GA 30329, in the original FRN. The meeting 
was published in the Federal Register on February 13, 2023, Volume 88, 
Number 29, page/s/ 9288-9289.
    The meeting is being amended to change the title of RFA-PS23-001, 
Increasing PrEP Use Among Disproportionately Affected Populations in 
the United States to RFA-PS23-001, Increasing PrEP Use Among Black 
Cisgender Women in the United States (HerPrEP) and to remove RFA-PS23-
003, Exploring Preferences for Long-Acting Antiretroviral Therapies 
(LA-ART) in a Community-Based Sample of Priority Populations Living 
with HIV Who are Disproportionately Affected and replace with RFA-PS23-
005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-
traditional Settings: Emergency Department. The date of the 
teleconference will also change and should read as follows:
    Date: May 24-25, 2023.
    Place: Teleconference, Centers for Disease Control and Prevention, 
Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.
    The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, National

[[Page 14373]]

Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 
Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone: 
(404) 718-8833, Email: [email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-04697 Filed 3-7-23; 8:45 am]
BILLING CODE 4163-18-P